Fargo, ND, October 2022
RxE2 is happy to announce a recent investment from Badlands Capital.
“I am so pleased to be working with Badlands Capital, especially since RxE2 is headquartered in Fargo, ND. The Badlands team truly understand what clinical trial innovation looks like and the magnitude of what RxE2 is and will accomplish, as we solve the recruitment, diversity, compliance, and retention issues for the pharmaceutical industry”, said Gerald Finken, CEO of RxE2.
The growth capital will be used to continue to scale RxE2’s technology and deliver clinical trials to diverse patient populations in more communities.
About Badlands Capital
Badlands Capital is a private equity firm in middle market companies located in South Dakota. The firm is focused on making minority growth and control investments, as well as control equity investment .
About RxE2
A leading digital health company focused on decentralized clinical trials led by community pharmacists. RxE2’s cutting-edge technology provides patient recruitment, dispensing, counseling, and operational services to the pharmaceutical and biotech industries.
